Abstract
Background: There is emerging data suggesting that the non-coding RNA (microRNA 193a or miR-193a) plays key roles in different types of cancers.
Objective: This review aims to investigate the functional significance of miR-193a in different cancers according to the information of literature.
Method: All the literature concerning miR-193a in cancer in PubMed are analysed.
Results: Several studies proved the association of miR-193a expression patterns with cancer’s stages, grades, response to the chemotherapy and even patient survival. Also, miR-193a can be used to differentiate some types of cancer. In cancer, miR-193a can act as a tumour suppressor gene or as an oncogene. Till now, several genetic factors (MAX, RXR α, XB130, P63, P73, AEG-1, HIFs, EGFR, Drosha, DGCR8, Dicer) and epigenetic factors (DNA methylation and long non-coding RNAs) were predicted to control miR-193a expression. They have fundamental effects on its biological behaviour in different types of cancers.
Conclusion: miR-193a has significant roles in cancer and can be targeted in the future for cancer therapy by better understanding of the factors that control its biological behaviour.
Keywords: miR-193a, cancer, chemotherapy, prognosis, mechanism, methylation.
Current Cancer Drug Targets
Title:Role of miR-193a in Cancer: Complexity and Factors Control the Pattern of its Expression
Volume: 18 Issue: 7
Author(s): Afraa Mamoori, Vinod Gopalan and Alfred K-Y Lam*
Affiliation:
- Cancer Molecular Pathology, School of Medicine, Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland,Australia
Keywords: miR-193a, cancer, chemotherapy, prognosis, mechanism, methylation.
Abstract: Background: There is emerging data suggesting that the non-coding RNA (microRNA 193a or miR-193a) plays key roles in different types of cancers.
Objective: This review aims to investigate the functional significance of miR-193a in different cancers according to the information of literature.
Method: All the literature concerning miR-193a in cancer in PubMed are analysed.
Results: Several studies proved the association of miR-193a expression patterns with cancer’s stages, grades, response to the chemotherapy and even patient survival. Also, miR-193a can be used to differentiate some types of cancer. In cancer, miR-193a can act as a tumour suppressor gene or as an oncogene. Till now, several genetic factors (MAX, RXR α, XB130, P63, P73, AEG-1, HIFs, EGFR, Drosha, DGCR8, Dicer) and epigenetic factors (DNA methylation and long non-coding RNAs) were predicted to control miR-193a expression. They have fundamental effects on its biological behaviour in different types of cancers.
Conclusion: miR-193a has significant roles in cancer and can be targeted in the future for cancer therapy by better understanding of the factors that control its biological behaviour.
Export Options
About this article
Cite this article as:
Mamoori Afraa , Gopalan Vinod and Lam K-Y Alfred *, Role of miR-193a in Cancer: Complexity and Factors Control the Pattern of its Expression, Current Cancer Drug Targets 2018; 18 (7) . https://dx.doi.org/10.2174/1568009618666180308105727
DOI https://dx.doi.org/10.2174/1568009618666180308105727 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biologics for ANCA-Associated Vasculitis
Inflammation & Allergy - Drug Targets (Discontinued) Pluripotency and Targeted Reprogramming: Strategies, Disease Modeling and Drug Screening
Current Drug Delivery Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design Polymer Drug Conjugates: Recent Advancements in Various Diseases
Current Pharmaceutical Design Quantification of Intracellular Proteins and Monitoring Therapy Using Flow Cytometry
Current Drug Targets Microwave-assisted Cycloaddition Reactions in Carbo- and Heterocyclic Chemistry
Current Organic Chemistry Lipid-Based Nanoparticulate Systems for the Delivery of Anti-Cancer Drug Cocktails: Implications on Pharmacokinetics and Drug Toxicities
Current Drug Metabolism Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Targeting the Perpetrator: Breast Cancer Stem Cell Therapeutics
Current Drug Targets N-Heterocyclic Dronic Acids: Applications and Synthesis
Mini-Reviews in Medicinal Chemistry Novel and Emerging Drugs for Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues
Current Medicinal Chemistry Computational Insights for the Discovery of Non-ATP Competitive Inhibitors of MAP Kinases
Current Pharmaceutical Design Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs as Main Players in the Pathogenesis of Chronic Lymphocytic Leukemia
MicroRNA Characterization of the Lymphotropic Amplicons-6 and Tamplicon-7 Vectors Derived from HHV-6 and HHV-7
Current Gene Therapy Perspectives Offered by Single-Domain Antibodies in Clinical Diagnostic of Pediatric Tumors
Current Medicinal Chemistry Oligonucleotides and Oligonucleotide Conjugates: A New Approach for Cancer Treatment
Current Medicinal Chemistry The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Deregulation of Apoptosis - Is it Still an Important Issue in Pathogenesis of Chronic Lymphocytic Leukemia?
Current Cancer Drug Targets